Agonist News and Research

RSS
Tirzepatide outperforms semaglutide in weight loss for overweight and obese adults

Tirzepatide outperforms semaglutide in weight loss for overweight and obese adults

Semaglutide linked to increased risk of severe eye condition NAION in new study

Semaglutide linked to increased risk of severe eye condition NAION in new study

Semaglutide and very-low calorie diet combo shows superior results in managing type 2 diabetes

Semaglutide and very-low calorie diet combo shows superior results in managing type 2 diabetes

Telehealth reduces stigma and barriers for addiction treatment, study finds

Telehealth reduces stigma and barriers for addiction treatment, study finds

TRPC5 gene identified as a diagnostic marker of obesity and postpartum depression

TRPC5 gene identified as a diagnostic marker of obesity and postpartum depression

Breakthrough prosthetic leg achieves natural gait through neural control

Breakthrough prosthetic leg achieves natural gait through neural control

Study reveals exercise and GLP-1 RA combination preserves bone health during weight loss

Study reveals exercise and GLP-1 RA combination preserves bone health during weight loss

Differences in effectiveness among antihyperglycemic drugs on dementia risk identified in recent study

Differences in effectiveness among antihyperglycemic drugs on dementia risk identified in recent study

New drug tirzepatide significantly improves sleep apnea and weight loss

New drug tirzepatide significantly improves sleep apnea and weight loss

Novo Nordisk presents key findings from semaglutide trials at ADA scientific sessions 2024

Novo Nordisk presents key findings from semaglutide trials at ADA scientific sessions 2024

High-resolution structures of SSTR5 reveal key interactions with neuropeptide and drug agonists

High-resolution structures of SSTR5 reveal key interactions with neuropeptide and drug agonists

Safety-focused summary of GLP-1 receptor agonists in diabetes, obesity, and beyond

Safety-focused summary of GLP-1 receptor agonists in diabetes, obesity, and beyond

Wegovy and Ozempic linked to reduced incidence and recurrence of alcohol abuse or dependence, study suggests

Wegovy and Ozempic linked to reduced incidence and recurrence of alcohol abuse or dependence, study suggests

Genetic discovery reveals key to inflammatory diseases

Genetic discovery reveals key to inflammatory diseases

Curcumin nanoparticles show promise in treating neurodegenerative diseases

Curcumin nanoparticles show promise in treating neurodegenerative diseases

Weight loss drug may change how obese people perceive taste

Weight loss drug may change how obese people perceive taste

Tirzepatide treatment results in successful weight loss regardless of obesity-related complications

Tirzepatide treatment results in successful weight loss regardless of obesity-related complications

Oral semaglutide shows significant promise in improving diabetes control and cardiovascular health, study reveals

Oral semaglutide shows significant promise in improving diabetes control and cardiovascular health, study reveals

Semaglutide shows significant kidney benefits in non-diabetic obese patients with heart disease

Semaglutide shows significant kidney benefits in non-diabetic obese patients with heart disease

New paper reveals the broad potential of TNIK as a therapeutic target for some aging-related diseases

New paper reveals the broad potential of TNIK as a therapeutic target for some aging-related diseases

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.